Clinical Trials
244 trialsPrecision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
ASSURE-3
Novartis
ASC4START
Novartis
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
Novartis
ASC2ADHERE
Novartis
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Sun Pharma Advanced Research Company Limited
Asciminib Roll-over Study
Novartis
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Novartis
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
ASC4TARGET
Novartis
Asciminib RMP Study
Novartis
ASC4INDIA
Novartis
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
Pfizer
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
DANTE
Novartis
CML
Enliven Therapeutics
TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
OPTIC
Takeda
CROSSCHECK-001
Crossbow Therapeutics, Inc.
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
CARDINAL
Terns, Inc.
Managed Access Programs for ABL001, Asciminib
Novartis
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
Novartis
ENESTfreedom
Novartis
TGRX-678 Pharmacokinetic Mass Balance
Shenzhen TargetRx Co., Ltd.
A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients
Novartis
ENESTop
Novartis
A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan
Novartis
HOPE
Ossium Health, Inc.
CML
Enliven Therapeutics
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
POLARIS-2
Ascentage Pharma Group Inc.
TGRX-678 Phase I Oral Pharmacokinetic Study
Shenzhen TargetRx Co., Ltd.
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Novartis
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Novartis
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Otsuka Beijing Research Institute
CARCML
Hikma Pharmaceuticals LLC
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Shenzhen TargetRx Co., Ltd.
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
ROOT
Taproot Health
ABL-2022-03
Novartis